Design of excitatory amino acid receptor agonists, partial agonists and antagonists: Ibotenic acid as a key lead structure

European Journal of Medicinal Chemistry

Volumn 31, Issue 7-8, 1996, Pages 515-537

  Krogsgaard Larsen, P ^a   Ebert, B ^a   Lund, T M ^a   Brauner Osborne H ^a   Slook F A ^a   Johansen, T N ^a   Brehm, L ^a   Madsen, U ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

AMPA agonist; AMPA antagonist; AMPA partial agonist; AMPA receptor modulator; EAA and Alzheimer's disease; EAA and neurodegeneration; EAA and schizophrenia; Excitatory amino acid (EAA) receptor; Functional partial agonism; Glycine agonist; Glycine antagonist; Glycine partial agonist; Ionotropic EAA receptor; Kainic acid agonist; Kainic acid antagonist; Metabotropic EAA agonist; Metabotropic EAA antagonist; Metabotropic EAA receptor; NMDA agonist; NMDA antagonist; Receptor autoradiography

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMINO ACID RECEPTOR STIMULATING AGENT; AMPA RECEPTOR; CYCLOTHIAZIDE; EXCITATORY AMINO ACID RECEPTOR; IBOTENIC ACID; KAINIC ACID; KAINIC ACID RECEPTOR; METABOTROPIC RECEPTOR; MILACEMIDE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT; QUINOLINIC ACID; QUISQUALIC ACID; RECEPTOR SUBTYPE; WILLARDIINE;

ALZHEIMER DISEASE; AUTORADIOGRAPHY; BINDING SITE; BRAIN REGION; CENTRAL NERVOUS SYSTEM; DEGENERATIVE DISEASE; DRUG DESIGN; DRUG RECEPTOR BINDING; HUMAN; NONHUMAN; PROTEIN STRUCTURE; RECEPTOR AFFINITY; REGULATORY MECHANISM; REVIEW; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION;

EID: 0029810754     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/0223-5234(96)89549-3     Document Type: Review

References (200)

1. 1 Watkins JC, Evans RH (1981) Annu Rev Pharmacol Toxicol 21, 165-204
2. 2 Barnard EA, Henley JM (1990) Trends Pharmacol Sci 11, 500-507
3. 3 Watkins JC, Krogsgaard-Larsen P, Honoré T (1990) Trends Pharmacol Sci 11, 25-33
4. 4 Dingledine R (1991) Trends Pharmacol Sci 12, 360-362
5. 5 Masu M, Tanabe Y, Tsuchida K, Shigemoto R, Nakanishi S (1991) Nature 349, 760-765
6. 6 Monyer H, Sprengel R, Schoepfer R et al (1992) Science 256, 1217-1221
7. 7 Tanabe Y, Masu M, Ishii T, Shigemoto R, Nakanishi S (1992) Neuron 8, 169-179
8. 8 Ishii T, Moriyoshi K, Sugihara H et al (1993) J Biol Chem 268, 2836-2843
9. 9 Seeburg PH (1993) Trends Pharmacol Sci 14, 297-303
10. 10 Henley JM (1994) Trends Pharmacol Sci 15, 182-190
11. 11 Hollmann M, Heinemann S (1994) Annu Rev Neurosci 17, 31-108
12. 12 Kamboj RK, Schoepp DD, Nutt S et al (1994) J Neurochem 62, 1-9
13. 13 Lodge D (ed) (1988) Excitatory Amino Acids in Health and Disease, John Wiley and Sons, Chichester
14. 14 Barnard EA, Costa E (eds) (1989) Allosteric Modulation of Amino Acid Receptors: Therapeutic Implications, Raven, New York
15. 15 Wheal H, Thomson A (eds) (1995) Excitatory Amino Acids and Synaptic Transmission, 2nd ed, Academic, London
16. 16 Simon RP (ed) (1992) Excitatory Amino Acids, Thieme, New York
17. 17 Watkins JC, Collingridge GL (eds) (1989) The NMDA Receptor, Oxford University, Oxford
18. 18 Moriyoshi K, Masu M, Ishii T, Shigemoto R, Mizuno N, Nakanishi S (1991) Nature 354, 31-37
19. 19 Johnson JW, Ascher P (1987) Nature 325, 529-531
20. 20 Thomson AM (1990) Prog Neurobiol 35, 53-74
21. 21 Ransom RW, Deschenes NL (1990) Synapse 5, 294-298
22. 22 Meldrum BS (ed) (1991) Excitatory Amino Acid Antagonists, Blackwell, Oxford
23. 23 Wong EHF, Kemp JA, Priestly T, Knight AR, Woodruff GN, Iversen LL (1986) Proc Natl Acad Sci USA 83, 7104-7108
24. 24 Yeh GC, Bonhaus DW, McNamara JO (1990) Mol Pharmacol 38, 14-19
25. 25 Monaghan DT, Olverman HJ, Nguyen L, Watkins JC, Cotman CW (1988) Proc Natl Acad Sci USA 85, 9836-9840
26. 26 Ebert B, Wong EHF, Krogsgaard-Larsen P (1991) Eur J Pharmacol Mol Pharmacol Sect 208, 49-52
27. 27 Priestley T, Kemp JA (1993) Mol Pharmacol 44, 1252-1257
28. 28 Krogsgaard-Larsen P, Honoré T, Hansen JJ, Curtis DR, Lodge D (1980) Nature (London) 284, 64-66
29. 29 Hansen JJ, Lauridsen J, Nielsen E, Krogsgaard-Larsen P (1983) J Med Chem 26, 901-903
30. 30 Hansen JJ, Nielsen B, Krogsgaard-Larsen P, Brehm L, Nielsen EØ, Curtis DR (1989) J Med Chem 32, 2254-2260
31. 31 Honoré T (1989) Med Res Rev 9, 1-23
32. 32 Sheardown MJ, Nielsen EØ, Hansen AJ, Jacobsen P, Honoré T (1990) Science 247, 571-574
33. 33 Krogsgaard-Larsen P, Ferkany JW, Nielsen EØ et al (1991) J Med Chem 34, 123-130
34. 34 Wahl P, Nielsen B, Krogsgaard-Larsen P, Hansen JJ, Schousboe A, Miledi R (1992) J Neurosci Res 33, 392-397
35. 35 Coyle JT (1983) J Neurochem 41, 1-11
36. 36 Shinozaki H (1992) In: Excitatory Amino Acid Receptors: Design of Agonists and Antagonists (Krogsgaard-Larsen P, Hansen JJ, eds) Ellis Horwood, Chichester, 261-291
37. 37 Johansen TH, Drejer J, Wätjen F, Nielsen EØ (1993) Eur J Pharmacol Mol Pharmacol Sect 246, 195-204
38. 38 Lerma J, Paternain AV, Naranjo JR, Mellström B (1993) Proc Natl Acad Sci USA 90, 11688-11692
39. 39 Monaghan DT, Bridges RJ, Cotman CW (1989) Annu Rev Pharmacol Toxicol 29, 365-402
40. 40 Schoepp DD, Bockaert J, Sladeczek F (1990) Trends Pharmacol Sci 11, 508-515
41. 41 Aramori I, Nakanishi S (1992) Neuron 8, 757-765
42. 42 Littman L, Glatt BS, Robinson MB (1993) J Neurochem 61, 586-593
43. 43 Schoepp DD, Johnson BG, Smith EC, McQuaid LA (1990) Mol Pharmacol 38, 222-228
44. 44 Birse EF, Eaton SA, Jane DE et al (1993) Neuroscience 52, 481-488
45. 45 Koerner JF, Johnson RL (1992) In: Excitatory Amino Acid Receptors: Design of Agonists and Antagonists (Krogsgaard-Larsen P, Hansen JJ, eds) Ellis Horwood, Chichester, 308-330
46. 46 Thomsen C, Kristensen P, Mulvihill E, Haldeman B, Suzdak PD (1992) Eur J Pharmacol Mol Pharmacol Sect 227, 361-362
47. 47 Nakanishi S (1992) Science 258, 597-603
48. 48 Drejer J (1992) In: Excitatory Amino Acid Receptors: Design of Agonists and Antagonists (Krogsgaard-Larsen P, Hansen JJ, eds) Ellis Horwood, Chichester, 352-375
49. 49 Sauer D, Fagg GE (1992) In: Excitatory Amino Acid Receptors: Design of Agonists and Antagonists (Krogsgaard-Larsen P, Hansen JJ, eds) Ellis Horwood, Chichester, 13-33
50. 50 Carlsson M, Carlsson A (1990) Trends Neurosci 13, 272-276
51. 51 Willetts J, Balster RL, Leander JD (1990) Trends Pharmacol Sci 11, 423-428
52. 52 Penney JB, Maragos WF, Greenamyre JT, Debowey DL, Hollingworth Z, Young AB (1990) J Neurol Neurosurg Psychiat 53, 314-320
53. 53 Greenamyre JT (1991) Neurobiol Aging 12, 334-336
54. 54 Deutsch SI, Mastropaolo J, Schwartz BL, Rosse RB, Morihisa JM (1989) Clin Neuropharmacol 12, 1-13
55. 55 Bowen DM (1990) Br J Psychiat 157, 327-330
56. 56 Greenamyre JT, Maragos WF (1993) Cerebrovas Brain Metab Rev 5, 61-94
57. 57 Bowen DM (1988) Age 11, 104-110
58. 58 Greenamyre JT, Young AB (1989) Neurobiol Ag 10, 593-602
59. 59 Beal MF (1992) Ann Neurol 31, 119-130
60. 60 Koh J, Yang LL, Cotman CW (1990) Brain Res 533, 315-320
61. 61 Kowall NW, Beal MF, Busciglio J, Duffy LK, Yankner BA (1991) Proc Natl Acad Sci USA 88, 7247-7251
62. 62 Marx J (1991) Science 253, 857-858
63. 63 Deutsch SI, Morihisa JM (1988) Clin Neuropharmacol 11, 18-35
64. 64 Jansen KLR, Faull RLM, Dragunow M, Synek BL (1990) Neuroscience 39, 613-627
65. 65 Carlson MD, Penney JB, Young AB (1993) Neurobiol Aging 14, 343-352
66. 66 Koh J, Choi DW (1988) J Neurosci 8, 2153-2163
67. 67 Weiss JH, Koh J, Baimbridge KG, Choi DW (1990) Neurology 40, 1288-1292
68. 68 Weiss JH, Choi DW (1991) Can J Neuroi Sci 18 (3, suppl), 394-397
69. 69 Choi DW (1989) Neurobiol Aging 10, 605-606
70. 70 Ebert B, Søby KK, Madsen U, Krogsgaard-Larsen P (1995) In: Schizophrenia - An Integrated View (Fog R, Gerlach J, Hemmingsen R, eds) Munksgaard, Copenhagen, 379-398
71. 71 Madsen U, Ebert B, Hansen JJ, Krogsgaard-Larsen P (1993) Eur J Pharmacol 230, 383-386
72. 72 Krogsgaard-Larsen P, Wahl P, Schousboe A, Madsen U, Hansen JJ (1993) Biochem Soc Trans 21, 102-106
73. 73 Ulas J, Cotman CW (1993) Schizophrenia Bull 19, 105-117
74. 74 Roberts GW, Bruton CJ (1990) Neumpathol Appl Neurobiol 16, 3-16
75. 75 Cotman CW, Monaghan DT (1988) Annu Rev Neurosci 11, 61-80
76. 76 Kerwin RW, Patel S, Meldrum BS (1990) Neuroscience 39, 25-32
77. 77 Sherman AD, Hegwood TS, Baruah S, Waziri R (1991) Biol Psychiat 30, 1191-1198
78. 78 Kornhuber J, Mack-Burkhardt F, Riederer P, Hebenstreit GF, Reynolds GP, Andrews HB, Bechmann H (1989) J Neural Transm 77, 231-236
79. 79 Ishimary M, Kurumaji A, Toru M (1994) Biol Psychiat 35, 84-95
80. 80 Barrett GC (ed) (1985) Chemistry and Biochemistry of the Amino Acids, Chapman and Hall, London
81. 81 Hansen JJ, Krogsgaard-Larsen P (1990) Med Res Rev 10, 55-94
82. 82 Krogsgaard-Larsen P, Hansen JJ (1992) Toxicol Lett 64/65, 409-416
83. 83 Krogsgaard-Larsen P, Hansen JJ (eds) (1992) Excitatory Amino Acid Receptors: Design of Agonists and Antagonists, Ellis Horwood, Chichester
84. 84 Nielsen EØ, Schousboe A, Hansen SH, Krogsgaard-Larsen P (1985) Neurochemistry 45, 725-731
85. 85 Watkins JC (1981) In: Glutamate: Transmitter in the Central Nervous System (Roberts PJ, Storm-Mathisen J, Johnston GAR, eds) John Wiley and Sons, Chichester, 1-24
86. 86 Nielsen EØ, Madsen U, Schaumburg K, Brehm L, Krogsgaard-Larsen P (1986) Eur J Med Chem - Chim Ther 21, 433-437
87. 87 Iwama T, Nagai Y, Tamura N, Harada S, Nagaoka A (1991) Eur J Pharmacol 197, 187-192
88. 88 Patneau DK, Mayer ML, Jane DE, Watkins JC (1992) J Neurosci 12, 595-606
89. 89 Kyle DJ, Patch RJ, Karbon EW, Ferkany JW (1992) In: Excitatory Amino Acid Receptors: Design of Agonists and Antagonists (Krogsgaard-Larsen P, Hansen JJ, eds) Ellis Horwood, Chichester, 121-161
90. 90 Hansen JJ, Jørgensen FS, Lund TM, Nielsen B, Reinhardt A, Breum I, Brehm L, Krogsgaard-Larsen P (1992) In: Excitatory Amino Acid Receptors: Design of Agonists and Antagonists (Krogsgaard-Larsen P, Hansen JJ, eds) Horwood, Chichester, 216-245
91. 91 Watkins JC, Olverman HJ (1987) Trends Neurosci 10, 265-272
92. 92 Wong EHF, Kemp JA (1991) Annu Rev Pharmacol Toxicol 31, 401-425
93. 93 Madsen U, Frydenvang K, Ebert B, Johansen TN, Brehm L, Krogsgaard-Larsen P (1996) J Med Chem 39, 183-190
94. 94 Brehm L, Jørgensen FS, Hansen JJ, Krogsgaard-Larsen P (1988) Drug News Perspect 1, 138-144
95. 95 Brehm L, Christensen IT, Nielsen B et al (1990) In: Frontiers in Drug Research (Jensen B, Jørgensen FS, Kofod H, eds) Munksgaard, Copenhagen, 92-105
96. 96 Krogsgaard-Larsen P, Nielsen EØ, Curtis DR (1984) J Med Chem 27, 585-591
97. 97 Krogsgaard-Larsen P, Brehm L, Johansen JS, Vinzents P, Lauridsen J, Curtis DR (1985) J Med Chem 28, 673-679
98. 98 Madsen U, Ferkany JW, Jones BE et al (1990) Eur J Pharmacol, Mol Pharmacol Sect 189, 381-391
99. 99 Johansen TN, Frydenvang K, Ebert B, Krogsgaard-Larsen P, Madsen U (1994) J Med Chem 37, 3252-3262
100. 100 Madsen U, Schaumburg K, Brehm L, Curtis DR, Krogsgaard-Larsen P (1986) Acta Chem Scand B40, 92-97
101. 101 Perkins MN, Stone TW (1983) J Pharmacol Exp Ther 226, 551-557
102. 102 Lunn WHW, Schoepp DD, Calligaro DO et al (1992) J Med Chem 35, 4608-4612
103. 103 Shinozaki H, Ishida M, Shimamoto K, Ohfune Y (1989) Brain Res 480, 355-359
104. 104 Curry K, Peet MJ, Magnuson DSK, McLennan H (1988) J Med Chem 31, 864-867
105. 105 Allan RD, Hanrahan JR, Hambley TW, Johnston GAR, Mewett KN, Mitrovic AD (1990) J Med Chem 33, 2905-2915
106. 106 McLennan H, Hall JG (1978) Brain Res 149, 541-545
107. 107 Watkins JC (1991) In: Excitatory Amino Acid Antagonists (Meldrum BS, ed) Blackwell Science, London, 84-100
108. 108 Ornstein PL, Klimkowski VJ (1992) In: Excitatory Amino Acid Receptors: Design of Agonists and Antagonists (Krogsgaard-Larsen P, Hansen JJ, eds) Ellis Horwood, Chichester, 183-200
109. 109 Hutchison AJ, Williams M, Angst C et al (1989) J Med Chem 32, 2171-2178
110. 110 Fagg GE, Olpe HR, Pozza MF et al (1990) Br J Pharmacol 99, 791-797
111. 111 Lehmann J, Schneider J, McPherson S et al (1987) J Pharmacol Exp Ther 240, 737-746
112. 112 Ornstein PL, Schoepp DD, Arnold MB et al (1991) J Med Chem 34, 90-97
113. 113 Kinney WA, Lee NE, Garrison DT et al (1992) J Med Chem 35, 4720-4726
114. 114 Iversen LL (1994) Neurotransmissions 10, 1-4
115. 115 Kemp JA, Foster AC, Wong EHF (1987) Trends Neurosci 10, 294-298
116. 116 Huettner JE, Bean BP (1988) Proc Natl Acad Sci USA 85, 1307-1311
117. 117 Lodge D (1992) In: Excitatory Amino Acid Receptors: Design of Agonists and Antagonists (Krogsgaard-Larsen P, Hansen JJ, eds) Ellis Horwood, Chichester, 201-215
118. 118 Lyle TA, Magill CA, Britcher SF et al (1990) J Med Chem 33, 1047-1052
119. 119 Leeson PD, Carling RW, James K et al (1990) J Med Chem 33, 1296-1305
120. 120 Rao TS, Cler JA, Emmett MR, Mick SJ, Iyengar S, Wood PL (1990) Neuropharmacology 29, 1075-1080
121. 121 Singh L, Donald AE, Foster AC et al (1990) Proc Natl Acad Sci USA 87, 347-351
122. 122 Benveniste M, Vyklicky L, Mayer ML, Clements J (1990) J Physiol 428, 333-357
123. 123 Mayer ML, Vyklicky L, Clements J (1989) Nature 338, 425-427
124. 124 Monahan JB, Corpus VM, Hood WF, Thomas JW, Compton RP (1989) J Neurochem 53, 370-375
125. 125 McBain CJ, Kleckner NW, Wyrick S, Dingledine R (1989) Mol Pharmacol 36, 556-565
126. 126 Snell LD, Morter RS, Johnson KM (1989) Eur J Pharmacol 156, 105-110
127. 127 Monahan JB, Hood WF, Compton RP, Cordi AA, Williams RM (1990) Eur J Pharmacol Mol Pharmacol Sect 189, 373-379
128. 128 Lodge D, Johnson KM (1990) Trends Pharmacol Sci 11, 81-86
129. 129 Singh L, Oles RJ, Tricklebank MD (1990) Br J Pharmacol 99, 285-288
130. 130 Leeson PD, Williams BJ, Baker R, Ladduwahetty T, Moore KW, Rowley M (1990) J Chem Soc, Chem Commun 1578-1580
131. 131 Hood WF, Compton RP, Monahan JB (1989) Neurosci Lett 98, 91-95
132. 132 Emmett MR, Mick SJ, Cler JA, Rao TS, Iyengar S, Wood PL (1991) Neuropharmacol 30, 1167-1171
133. 133 Kemp JA, Leeson PD (1993) Trends Pharmacol Sci 14, 20-25
134. 134 Jacobsen P, Naerum L, Nielsen FE, Honoré T (1992) In: Excitatory Amino Acid Receptors: Design of Agonists and Antagonists (Krogsgaard-Larsen P, Hansen JJ, eds) Ellis Horwood, Chichester, 246-260
135. 135 Leeson PD, Baker R, Carling RW et al (1991) J Med Chem 34, 1243-1252
136. 136 Leeson PD, Carling RW, Moore KW et al (1992) J Med Chem 35, 1954-1968
137. 137 Kulagowski JJ, Baker R, Curtis NR et al (1994) J Med Chem 37, 1402-1405
138. 138 Madsen U, Ebert B, Krogsgaard-Larsen P (1994) Biomed Pharmacother 48, 305-311
139. 139 Honoré T, Lauridsen J, Krogsgaard-Larsen P (1982) J Neurochem 38, 173-178
140. 140 Honoré T, Nielsen M (1985) Neurosci Lett 54, 27-32
141. 141 Murphy DE, Snowhill EW, Williams M (1987) Neurochem Res 12, 775-782
142. 142 Christensen IT, Reinhardt A, Nielsen B et al (1989) Drug Des Del 5, 57-71
143. 143 Ebert B, Lenz SM, Brehm L et al (1994) J Med Chem 37, 878-884
144. 144 Ebert B, Madsen U, Lund TM, Lenz SM, Krogsgaard-Larsen P (1994) Neurochem Int 24, 507-515
145. 145 Madsen U, Ebert B, Krogsgaard-Larsen P, Wong EHF (1992) Eur J Med Chem 27, 479-484
146. 146 Madsen U, Frølund B, Lund TM, Ebert B, Krogsgaard-Larsen P (1993) Eur J Med Chem 28, 791-800
147. 147 Skjærbæk N, Ebert B, Falch E, Brehm L, Krogsgaard-Larsen P (1995) J Chem Soc, Perkin Trans I 221-225
148. 148 Lauridsen J, Honoré T, Krogsgaard-Larsen P (1985) J Med Chem 28, 668-672
149. 149 Madsen U, Brehm L, Schaumburg K, Jørgensen FS, Krogsgaard-Larsen P (1990) J Med Chem 33, 374-380
150. 150 Madsen U, Wong EHF (1992) J Med Chem 35, 107-111
151. 151 Ebert B, Madsen U, Lund TM, Holm T, Krogsgaard-Larsen P (1992) Mol Neuropharmacol 2, 47-49
152. 152 Krogsgaard-Larsen P, Hansen JJ, Lauridsen J, Peet MJ, Leah JD, Curtis DR (1982) Neurosci Lett 31, 313-317
153. 153 Turski L, Jacobsen P, Honoré T, Stephens DN (1992) J Pharmacol Exp Ther 260, 742-747
154. 154 Hansen JJ (1993) Curr Top in Med Chem 1, 377-385
155. 155 Bischoff F, Johansen TN, Ebert B, Krogsgaard-Larsen P, Madsen U (1995) Bioorg Med Chem 3, 553-558
156. 156 Christensen IT, Ebert B, Madsen U, Nielsen B, Brehm L, Krogsgaard-Larsen P (1992) J Med Chem 35, 3512-3519
157. 157 Honoré T, Davies SN, Drejer J et al (1988) Science 241, 701-703
158. 158 Honoré T, Drejer J, Nielsen EØ, Nielsen M (1989) Biochem Pharmacol 38, 3207-3212
159. 159 Ohmori J, Sakamoto S, Kubota H et al (1994) J Med Chem 37, 467-475
160. 160 Ornstein PL, Arnold MB, Augenstein NK, Lodge D, Leander JD, Schoepp DD (1993) J Med Chem 36, 2046-2048
161. 161 Frandsen A, Krogsgaard-Larsen P. Schousboe A (1990) J Neurochem 55, 1821-1823
162. 162 Madsen U, Bang-Andersen B, Brehm L et al (1996) J Med Chem 39. 1682-1691
163. 163 Rogawski MA (1993) Trends Pharmacol Sci 14, 325-331
164. 164 Tarnawa I, Farkas S, Berzsenyi P, Pataki A, Andrási F (1989) Eur J Pharmacol 167, 193-199
165. 165 Smith S, Meldrum BS (1992) Stroke 23, 861-864
166. 166 Arvin B, Lekieffre D, Graham JL, Moncada C, Chapman AG, Meldrum BS (1994) J Neurochem 62, 1458-1467
167. 167 Smith SE, Dürmüller N, Meldrum BS (1991) Eur J Pharmacol 201, 179-183
168. 168 Patneau DK, Mayer ML (1991) Neuron 6, 785-798
169. 169 Lerma J, Morales M, Ibarz JM, Somohano F (1994) Eur J Neurosci 6, 1080-1088
170. 170 Yamada KA, Tang CM (1993) J Neurosci 13, 3904-3915
171. 171 Zorumski CF, Yamada KA, Price MT, Olney JW (1993) Neuron 10, 61-67
172. 172 Isaacson JS, Nicoll RA (1991) Proc Natl Acad Sci USA 88, 10936-10940
173. 173 Tsuzuki K, Takeushi T, Ozawa S (1992) Mol Brain Res 16, 105-110
174. 174 Arai A, Kessler M, Xiao P, Ambrosingerson J, Rogers G. Lynch G (1994) Brain Res 638, 343-346
175. 175 Shinozaki H (1988) Prog Neurobiol 30, 399-435
176. 176 Hashimoto K, Shirahama H (1990) In: Amino Acids: Chemistry, Biology and Medicine (Lubec G, Rosenthal GA, eds) ESCOM. Leiden, 566-572
177. 177 Nakanishi S (1994) Neuron 13, 1031-1037
178. 178 Desai MA, Conn PJ (1991) J Neurophysiol 66, 40-52
179. 179 Nakagawa Y, Saitoh K, Ishihara T, Ishida M, Shinozaki H (1990) Eur J Pharmacol 184, 205-206
180. 180 Porter RHP, Roberts PJ, Jane DE, Watkins JC (1992) Br J Pharmacol 106, 509-510
181. 181 Chung DS, Winder DG, Conn PJ (1994) J Neurochem 63, 133-139
182. 182 Eaton SA, Jane DE, Jones PLS et al (1993) Eur J Pharmacol Mol Pharmacol Sect 244, 195-197
183. 183 Jane DE, Jones PLS, Pook PCK, Salt TE, Sunter DC, Watkins JC (1993) Neuropharmacology 32, 725-727
184. 184 Hayashi Y, Sekiyama N, Nakanishi S et al (1994) J Neurosci 14, 3370-3377
185. 185 Bräuner-Osborne H, Sløk FA, Skjærbæk N et al (1996) J Med Chem 39, in press
186. 186 Javitt DC, Zukin SR (1991) Am J Psychiatry 148, 1301-1308
187. 187 Costa J, Khaled E, Sramek J, Bunney WE, Potkin S (1990) J Clin Psychopharmacol 10, 71-72
188. 188 Rosse RB, Schwartz BL, Davis RE, Deutsch SI (1991) Clin Neuropharmacol 14, 268-272
189. 189 Aniksztejn L, Charton G, Ben-Ari Y (1987) Brain Res 404, 58-64
190. 190 Davies SN, Alford ST, Coan EJ, Lester RAJ, Collingridge GL (1988) Neurosci Lett 92, 213-217
191. 191 Egebjerg J, Bettler B, Hermans-Borgmeyer I, Heinemann S (1991) Nature 351, 745-748
192. 192 Martin LJ, Blackstone CD, Levey AI, Huganir RL, Price DL (1993) Neuroscience 53, 327-358
193. 193 Porter RHP, Greenamyre JT (1994) Brain Res 664, 202-206
194. 194 Boulter J, Hollmann M, O'Shea-Greenfield A et al (1990) Science 249, 1033-1037
195. 195 Bettler B, Boulter J, Hermans-Borgmeyer I et al (1990) Neuron 5, 583-595
196. 196 Petralia RS, Wenthold RJ (1992) J Comp Neurol 318, 329-354
197. 197 Nielsen EØ, Cha JHJ, Honoré T, Penney JB, Young AB (1988) Eur J Pharmacol 157, 197-203
198. 198 Leatherbarrow TJ (1992) Grafit Version 3.0. Erithacus Software, Staines, UK
199. 199 Ebert B, Madsen U, Søby KK, Krogsgaard-Larsen P (1996) Neurochem Int (in press)
200. 200 Arnt J, Sánchez C, Lenz SM, Madsen U, Krogsgaard-Larsen P (1995) Eur J Pharmacol 285, 289-297